Regeneron Pharmaceuticals, Inc. Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.4%projected annual EPS growth
Analyst Coverage
27analysts covering
FY Revenue (est.)
$16.9Bnext fiscal year
FY EPS (est.)
$53.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 28 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly total revenue (USD billions) Quarterly4.3
Quarterly global Dupixent net sales reported by Sanofi (USD billions) Quarterly6.0
Quarterly U.S. EYLEA HD net sales (USD billions) Quarterly0.6
Watch Items
- Fianlimab pivotal-program execution following the first-line melanoma Phase 3 primary-endpoint missAction: Reassess oncology-pipeline probability assumptions and remove material unapproved fianlimab value from the investment case.
- Cemdisiran FDA review for generalized myasthenia gravisAction: Reassess near-term pipeline diversification, launch timing, and the probability assigned to the bull case.
Research as of 29 Aug 2026